Company / Shareholders' Equity
Moderna Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$8.7B
FY2025
5-year range
$1.2B / $13.9B
FY2021-FY2025
Trend
-20.6%
vs FY2024
Sector context
#14 of 213
Health Care
What the data says
Among 213 Health Care companies, Moderna is in the top 7% for shareholders' equity. Shareholders' Equity has fluctuated over the past 10 years, ranging from -$551M in FY2017 to $13.9B in FY2023.
Based on SEC 10-K filings.
$8.7B in FY2025 with a 5-year CAGR of +27.6%. Top quartile in the Health Care sector.
Declined from $13.9B to $8.7B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +50.0%
- 5-Year CAGR
- +27.6%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 213This company $8.7B Sector average $2.5B
▼
+239.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +27.6%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 20.6% year-over-year.
- Ranks #14 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.7B | -20.6% |
| FY2024 | $10.9B | -21.3% |
| FY2023 | $13.9B | +441.0% |
| FY2022 | $2.6B | +118.0% |
| FY2021 | $1.2B | -54.1% |
| FY2020 | $2.6B | +118.0% |
| FY2019 | $1.2B | -23.2% |
| FY2018 | $1.5B | +377.5% |
| FY2017 | -$551.4M | -64.7% |
| FY2016 | -$334.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026